Navigation Links
Immunosyn Corporation Files 10-Q
Date:5/16/2008

abetic ulcers. Immunosyn went public in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol "IMYN."

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whe
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
3. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
4. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
5. Immunosyn Corporation Names G. David Criner as CFO
6. Immunosyn Corporation to Present at FSX
7. CorVel Corporation Announces Earnings Release Webcast
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
10. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... 30, 2014 Genedata, a ... drug discovery and related life science research, ... chosen Genedata Selector as its host-pathogen data ... FUNGITECT is a European consortium dedicated to ... via individualized anti-fungal drug therapies. Genedata Selector ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... ... the slate of SDS Clinical Trials. Nissan Pilest, Medical Director of Total Dermatology in Irvine, ... ... Well known Orange County Dermatologist and Laser Physician, Nissan Pilest , has been selected ...
... PRINCETON, N.J., July 28 Laureate Pharma, ... today announced the appointment of Daniel E. Leone as ... responsible for Laureate,s worldwide business development activities, including sales ... contract development, manufacturing, and bioprocessing business. , ...
... , DOYLESTOWN, Pa., July 28 ... company to offer a broad range of accredited CME courses in ... clinical trials. , , The comprehensive education and ... Institute (BRITI)(TM). RadMD is partnering with International Center for Postgraduate Medical ...
Cached Biology Technology:Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division 2Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development 2RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials 2
(Date:9/30/2014)... of moorland burning is published today in the first ... of relieving tensions on both sides of the grouse ... Moorland Burning on the Ecohydrology of River basins) project ... practised predominantly to support red grouse populations for gun ... chemistry and physical properties, river water chemistry and river ...
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... and strawberries all have in common? Unlike most ... and are diploid, these organisms are all polyploid, meaning ... and salmon have 3 and 4 sets of chromosomes, ... seem surprising, in fact most plant species are polyploid. ... century ago, but only recently, with the development of ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4
... all likely to blame for poisoning the waters being drained from ... is leaving behind -- also owes its contamination to a source ... environments that made their way en masse into the water as ... Florida professor who has spent years studying the harmful contaminants that ...
... conditions and diseases is both feasible and safe, report ... the approach in patients with advanced rheumatoid arthritis. The ... Proceedings of the National Academy of Sciences (PNAS), indicate ... block the destructive inflammation process that takes place within ...
... the number of voices they hear to the number ... have found. The finding indicates that numerical perception is ... of a particular sense, said the researchers. The experimental ... human infants, before they have a verbal capacity, understand ...
Cached Biology News:Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 2Results of world's first gene therapy trial for arthritis show approach safe, feasible 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 4Monkeys understand numbers across senses 2
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... sample is a complex protein sample, ... when used with ReadyPrep 2-D starter ... sample can be used as a ... and protocol before using more difficult ...
... materials for 1,464 array sample elements. , ,Includes: ... , Blocker BSA in PBS (10X): 50 ml ... g , BupH Phosphate Buffered Saline: ... 2 x 10 ml ampules , SuperSignal West Pico ...
... Mouse polyclonal antibody raised ... Immunogen: ... 112 a.a) partial recombinant protein ... Accession Number: NM_130777 ...
Biology Products: